Mitosis Inhibitor Dosing Schedule for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosing schedules for mitosis inhibitors often fail to balance potent biological activity with manageable toxicity, particularly in cancer treatment, leading to adverse side effects.
Innovation Solution
Administering two doses of a mitosis inhibitor between the biologically effective dose and the maximum tolerated dose, with the second dose given 24 to 48 hours after the first, in a 14 to 21 day dosing cycle, to maintain mitotic arrest and induce apoptosis while allowing for side effect recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single high dose of mitosis inhibitor is administered, then potent biological activity is achieved, but toxicity increases
Solution Approach 1:
The patent divides a single high dose into multiple lower doses administered at different time points (e.g., Day 1 and Day 8). This segmentation maintains cumulative biological activity while reducing peak toxicity, allowing normal tissues to recover between doses. The split dosing schedule specifically addresses the contradiction by delivering the same total drug exposure in a less toxic manner.
Solution Approach 2:
The patent implements periodic dosing schedules with specific intervals (e.g., every 8 days, or Days 1 and 8 of a 14-day cycle). This periodic administration maintains therapeutic effect while allowing recovery periods that reduce cumulative toxicity. The rhythmic dosing pattern enables the body to eliminate excess drug and regenerate healthy tissues between treatments.
2Object-affected harmful factors
If the dosing cycle is extended to allow side effect recovery, then toxicity is reduced, but treatment duration increases
Solution Approach 1:
The patent employs dynamic dosing schedules that are tailored to the specific pharmacokinetics and toxicology of each mitosis inhibitor. Dosing intervals are optimized based on drug half-life, tissue recovery rates, and therapeutic window characteristics. This dynamic approach ensures the shortest possible treatment duration that still allows adequate recovery, avoiding both excessive toxicity and unnecessarily prolonged treatment.
3Duration of action of moving object
If multiple doses are administered within a short interval, then mitotic arrest duration is extended, but side effects accumulate
Solution Approach 1:
The patent schedules multiple doses in advance according to pre-determined intervals that predictably extend mitotic arrest while avoiding toxic accumulation. The dosing schedule is designed beforehand based on pharmacokinetic modeling and clinical data, specifying exact timing (e.g., Day 1 and Day 8) to achieve optimal mitotic disruption before side effects become problematic.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This dosing schedule enhances the duration and magnitude of apoptosis, reducing toxicity and improving treatment efficacy for cancer and hyperproliferative diseases by maintaining cells in mitotic arrest long enough to induce cell death without excessive side effects.
Implementation Method 1
Vinca alkaloids inhibit microtubule polymerization, which thereby inhibits mitosis
Implementation Method 2
Taxanes stabilize microtubules, thereby inactivating the microtubule function of a cell and inhibiting cell division
Implementation Method 3
This dosing schedule enhances the duration and magnitude of apoptosis, reducing toxicity and improving treatment efficacy for cancer and hyperproliferative diseases by maintaining cells in mitotic arrest long enough to induce cell death without excessive side effects
Data Source
AI summary
Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.